Abstract: The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.

Abstract: Compounds for use The invention relates to a combination comprising (i) a compound A comprising a mitochondrial targeting group linked to a group capable of releasing hydrogen sulfide or a pharmaceutically acceptable salt thereof or a prodrug thereof, an inhibitor of the thioredoxin antioxidant system or pharmaceutically acceptable salt thereof or a prodrug thereof, and/or a nitroxide or a pharmaceutically acceptable salt thereof or a prodrug thereof; and (ii) a photosensitizer or photosensitizer precursor; for use in photodynamic therapy.

Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.

Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.

Abstract: Polyurethane microparticles are derived from structural units comprising poly(alkylene oxide) moieties, caprolactone moieties and urethane moieties. The microparticles may include an active agent and have a particle size from 0.1 to 100 microns. Microparticles for injection have a particle size of 15 to 80 microns; for use as a aerosol 1 to 3 microns; and for intraocular use 0.02 to 2 microns. Dispersivity is in the range 1 to 3.

Abstract: The present invention is directed to a composition comprising (a) cabazitaxel and (b) sulfobutyl ether beta cyclodextrin. Such composition exhibits unexpectedly desirable stability in aqueous media, permitting therapeutic dosages of the drug to be administered without the use of either ethanol or surfactants.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using them are also provided.

Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.

Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Abstract: Methods are disclosed herein for treating a subject with a lung cancer. The lung cancer can be small cell carcinoma of the lung or non-small cell carcinoma of the lung. The methods include locally administering to the subject a therapeutically effective amount of the polyketal particle comprising a CpG oligodexoynucleotide. Optionally, the polyketal particle can include an imidazoquinoline compound.

Abstract: Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.

Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

Abstract: This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

Abstract: A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.

Abstract: The present disclosure provides methods for reducing bioburden on a tissue product, as well as the tissue products produced according to the disclosed methods. In particular, the disclosure relates to methods of electroporating tissue in the presence of one or more bactericides in order to reduce bioburden. The methods allow for reduced exposure to electrical energy and/or bactericide while reducing bioburden.

Abstract: The air compressor has an air intake, a tank, means for pressurizing the air in the tank and an air outlet connected to the tank. High power UV LED light sources are mounted within the tank to disinfect the interior tank surface. The UV LED light sources preferably have an output wavelength within the range of 250 nm to 365 nm, most preferably within the range of 260 nm to 270 nm. Preferably, the light output of the light sources is pulsed. The light source has a cover for protecting the light source which may take the form of a quartz diverging lens. Air flow is directed through the area proximate the light source to remove particles from the light source cover. The effect of this air flow can be amplified by creating turbulence proximate the light sources utilizing a member with an arcuate profile.

Abstract: Ultraviolet radiation is directed within an area. Items located within the area and/or one or more conditions of the area are monitored over a period of time. Based on the monitoring, ultraviolet radiation sources are controlled by adjusting a direction, an intensity, a pattern, and/or a spectral power of the ultraviolet radiation generated by the ultraviolet radiation source. Adjustments to the ultraviolet radiation source(s) can correspond to one of a plurality of selectable operating configurations including a storage life preservation operating configuration, a disinfection operating configuration, and an ethylene decomposition operating configuration.

Abstract: Systems and methods for sanitization of surfaces, such as hands, are provided. In general, the described techniques utilize a system including a housing having an active agent receptacle in fluid communication with at least one nozzle, and an air pump in fluid communication with the at least one nozzle. The system also includes a control module configured to control the delivery of an active agent as an aerosol spray through the at least one nozzle in a delivery dose. The delivery dose is expelled onto the surface as a thin uniform layer and dried such that the entire surface sanitization process is completed in less than or equal to 5 seconds. The active agent receptacle can be configured to receive a removable and replaceable cartridge carrying the active agent.

Abstract: A fragrance dispenser, in particular for a heating, ventilation, and air conditioning system, with a fragrance container with a connection opening and with a container cover with an air inlet channel and an air outlet channel, further, with a movable operating element, and a movable valve element by means of which the air inlet channel and the air outlet channel can be opened and closed, wherein the valve element can be actuated by the operating element, and wherein further a bypass channel can be controlled by the operating element.

Abstract: A sealing member is disclosed for use with a wick of a diffuser, or the like. The sealing member seals a vessel containing a liquid in a fluid chamber. The sealing member may be composed of a malleable material that may also be resistant to a liquid fragrance contained in the vessel. The sealing member may include a body, flaps and an opening for receiving a wick therethrough. The sealing member may form a persistent seal when a wick is inserted therethrough, while at the same time allowing venting to the fluid chamber.

Abstract: Provided according to some embodiments of the invention are wound dressings that include a polymer matrix and nitric oxide-releasing polysiloxane macromolecules within and/or on the polymer matrix. Also provided are wound dressing kits and methods of using and forming such wound dressings.

Abstract: The disclosed hydrophobic adhesive composition comprises a hydrophobic adhesive matrix and water absorbent fibers dispersed throughout the adhesive matrix to provide water management capabilities to the adhesive composition. The disclosed adhesive composition can adhered to a variety of surfaces, such as skin, and will easily remove from the surface. Therefore, the disclosed adhesive is particularly well suitable for application to skin wherein the absorbent fiber can absorb perspiration, water, or wound fluid from skin.

Abstract: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homo-polymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.

Abstract: Certain embodiments described herein are directed to cohesive materials comprising treated, derivatized collagen molecules. In some embodiments, the cohesive material can function as a putty or defect filler that can be used in a tissue repair. Methods of using the cohesive materials are also described.

Abstract: Biodegradable single-phase cohesive hydrogels useful, e.g., for the formulation of viscosupplementation compositions or compositions for filling wrinkles, contain a homogeneous blend of x polymers, which may be identical or different, crosslinked prior to the interpenetration thereof by mixing in the form of a single-phase hydrogel, wherein such crosslinked polymers are insoluble in water and miscible with one another, and x ranges from 2 to 5; in one embodiment, the hydrogels are such that the x polymers have identical or different degrees of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2, with x1 being greater than or equal to x2.

Abstract: A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent.

Abstract: A tympanic construct fabricated from at least one amniotic membrane, at least one chorionic membrane, or at least one amniotic membrane and at least one chorionic membrane obtained from human birth tissue is provided. Methods of preparing a tympanic construct, methods of repairing tympanic membrane defects and surgical sites, as well as kits for the same are also provided.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

Abstract: A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.

Abstract: Embodiments relate to an ophthalmology microscopy-system and a method of operating an ophthalmology microscopy-system which allow for an at least partial or full removal of liquids and gels used in ophthalmology for application in an eye of a patient in an particularly efficient way. Further embodiments relate to a product such as a liquid or a gel usable for an application in an eye of a patient, wherein the product has a high transmittance and, nevertheless, may be made visible particularly well.

Abstract: The invention provides for an improved medical device used to remove gas and liquid from the plural cavity between the lung and the chest wall in both stationary and mobile applications. The present invention generally comprises a hollow needle with a hollow closed end stylet slidably received in the needle. The stylet is spring-biased to extend out of the needle end as a safety tip but when pressured is moved to a retracted position to allow for insertion through the chest wall. The pressure needed to insert the needle/stylet combination through the chest wall is applied by a housing at the end of the needle which is contoured for easy grip. While not being applied to the chest wall, the stylet comprises a safety tip, which makes the device safe to handle and apply in stationary or mobile applications. Further, the housing includes a one-way valve is configured permit only the passage of air and bodily fluid out of the pleural cavity without a secondary structure needed.

Abstract: A device for controlling blood flow occurring in a haemorrhagic zone of a biological tissue, includes a flexible plate arranged to be placed opposite this zone, the flexible plate including: substantially leaktight peripheral supporting elements, for applying on the tissue so that the zone is surrounded; a back wall delimiting, with the supporting elements, opposite the zone, a hollow space; connecting elements connecting the hollow space, externally to the flexible plate, to an external aspiration source for creating a vacuum in the hollow space for aspirating and tightly applying the surface of the tissue against the peripheral supporting elements; and a hollow stud placed between the zone and the back wall and hollowed out in its center on the side of the zone along an axis substantially perpendicular to the back wall, and arranged to be in contact with the zone when the vacuum is created in the space.

Abstract: A breast pump system includes a vacuum break backflow preventer for preventing breast milk from accidentally backflowing into a suction tube leading to a vacuum pump. The backflow preventer is a vacuum passageway with two spaced apart suction openings. The two openings convey air to cyclically pressurize and depressurize a small milk charging chamber. If milk accidentally covers one of the openings, air at the other opening minimizes the pressure differential that might otherwise draw the milk deep into the suction tube and toward the vacuum pump. For ease of cleaning and sanitizing, the system avoids or minimizes the use of baffles, permanently enclosed passageways, moving parts, and tight inside corners. Some passageways can be split open for access during cleaning. To make the breast milk collection device less protruding under a brassier, the vacuum passageway curves around the side of a nipple receptacle rather than in front of it.

Abstract: A total artificial heart for a mammalian cardiovascular system is provided. The total artificial heart has a pump casing including an outer housing and an integral hollow support shaft extending therethrough. The casing defines a first flow path within the outer housing about an exterior of the hollow support shaft and a separate second flow path extending within the hollow support shaft. An annular impeller is housed within the outer housing of the casing for rotation about the hollow support shaft to provide a centrifugal flow pump in the first flow path, and an axial flow impeller is housed within the hollow support shaft of the casing for forming an axial flow pump in the second flow path.

Abstract: A blood flow conduit includes a first conduit portion defining a first portion of a lumen; and a second conduit portion defining a second portion of a lumen. At least one of the first or second conduit portions may include a tip portion and the other of the first or second conduit portions may include an enlarged area.

Abstract: The catheter device comprises a drive shaft connected to a motor, and a rotor mounted on the drive shaft at the distal end section. The rotor has a frame structure which is formed by a screw-like boundary frame and rotor struts extending radially inwards from the boundary frame. The rotor struts are fastened to the drive shaft by their ends opposite the boundary frame. Between the boundary frame and the drive shaft extends an elastic covering. The frame structure is made of an elastic material such that, after forced compression, the rotor unfolds automatically.

Abstract: The present invention provides devices, systems, and methods for control of ventricular assist devices. The invention includes an implantable controller that is operatively programmed to direct physiological flow through a ventricular assist device that is substantially synchronized to the cardiac cycle of the subject. The implantable controller is also communicatively connected to an external control unit, such that the implantable controller can transmit data to the external control unit, and instructions can be sent from the external control unit to the implantable controller.

Abstract: A heart pump includes a rotative impeller partly inserted into the systemic ventricle, this rotative impeller being equipped with a membrane sutured to the outer wall of the heart in such a way as to secure the rotative impeller to the wall of the heart, a housing arranged inside the systemic ventricle in such a way as to draw up then discharge blood, a motor connected to the housing and arranged partly outside the systemic ventricle in such a way as to facilitate maintenance; an integrated management unit in the epigastric region including a power supply and a rotative impeller control unit; and a wired link between the management unit and the rotative impeller.

Abstract: A balancing unit for medical fluids includes at least one balancing chamber and at least one conveying unit for filling the balancing chamber, in which the conveying unit is a pressure controlled conveying unit and/or is designed and provided for being operated in at least one operating state as a constant-pressure source. An external medical functional unit, a treatment apparatus and methods are also described.

Abstract: A dialysis system including a housing, a dialysate pump disposed in the housing, and a dialysate line configured to be operatively connected to the dialysate pump such that the dialysate pump can pump dialysate through the dialysate line when the dialysate line is in fluid communication with a dialysate source.

Abstract: Blood separation systems and methods are provided for detecting lipids in plasma that has been separated from a plasma-containing fluid, such as blood. Plasma is separated from a fluid in a blood separator, with at least a portion of the separated plasma being removed from the blood separator via a plasma flow path. Blue and/or ultraviolet light is passed through the separated plasma in the blood separator or in the plasma flow path, with at least a portion of the light being received after passing through the separated plasma. A signal is generated based on the amount of light passing through the separated plasma, with the signal being indicative of the lipid content of the separated plasma. Determining the lipid content of the separated plasma involves comparing the difference between the signal and a reference signal that represents receipt of all or a pre-selected amount of the light.

Abstract: An irrigation system, useable e.g. for rectal/anal irrigation, comprising a reservoir for irrigating liquid; a probe (such as a catheter) for arrangement in a user, and having an inflatable retention member (such as a balloon); and tubing providing fluid communication between the reservoir, the control unit and the probe for conducting the irrigation fluid from the reservoir to the probe.

Abstract: A cartridge set including: a plurality of cartridges; a plurality of holders, each of which has an upper end externally fitted to the outer peripheral surface of each of the cartridges, and has a lower end face whose outer diameter is greater than the outer diameter of the outer peripheral surface of the cartridge; a supporting plate that has a plurality of through-holes, each of which has an inner diameter greater than the outer diameter of the outer peripheral surface of the cartridge and has each of the plurality of cartridges inserted therethrough; a storage box that stores the supporting plate therein; and a lid member that blocks an upper end opening of the storage box.

Abstract: An intravenous (IV) set system comprising a primary IV set defining a primary flow line of the IV set system. The primary flow line can include multiple access points along its length and feeds to a merging fluid pathway proximate to the distal terminus of the primary IV set. At least one secondary IV set with corresponding flow lines can be separably joined to the primary IV set to cause the secondary flow lines to be in fluid communication with the primary flow line. At least one of the IV sets can have a unique set of uniform marking indicia to facilitate rapid identification of the IV sets from other IV sets within the IV set system. Such marked and identified primary and/or secondary IV sets can be allocated to specific medical functions and/or can be for use by specific medical personnel to thereby minimize risk of error in administration of an IV to a patient. The IV set system can further comprise a merging fluid pathway about a primary IV set.

Abstract: Some embodiments of an infusion pump system include a pump device with a drive system that is configured to attach with a medicine cartridge in manner that reduces the likelihood of dosage inaccuracies. In one example, the drive system of the pump device can be equipped with a plunger engagement device that is configured to mechanically anchor into a plunger of the medicine cartridge, and then to bias the plunger of the medicine cartridge in a direction toward a piston rod of the drive system.

Abstract: A drug delivery device (100), including a body (104, 116) having a reservoir (164, 176) disposed therein for containing a medicament and an injection needle (152) for penetrating the skin of a patient, the needle (152) providing a path for the medicament between the reservoir (164, 176) and the patient. The device (100) also includes a needle cover (114) for selectively covering the injection needle (152), an adhesive (264) for selectively adhering the device to the patient, a release liner (500) for selectively covering a patient side of the adhesive (264), and a connecting means (112, 520, 512, 508, 524) for connecting the needle cover (114) and the release liner (500) such that removal of one of the needle cover (114) and the release liner (500) from the device (100) removes the other one of the needle cover (114) and the release liner (500).